Boehringer to expand oncology presence with $572m Tessellate Bio deal
Pharmaceutical Technology
APRIL 23, 2025
The agreement gives Boehringer access to Tessellates novel approach targeting ALT-dependent tumours.
Wed.Apr 23, 2025
243 
Bristol Myers’ prized schizophrenia drug stumbles in testing
Bio Pharma Dive
APRIL 23, 2025
A late-stage study found Cobenfy wasn’t better than a placebo as an add-on to atypical antipsychotics. Some analysts view the failure as a “significant hit” to the drug’s commercial outlook.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing
Pharmaceutical Technology
APRIL 23, 2025
The lawsuit filings are the latest turn in a long-running legal saga between GLP-1RAs makers and compounders.
German antibody maker valued at $1.6B in blank-check merger
Bio Pharma Dive
APRIL 23, 2025
The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T cell engagers and bispecific drugs for cancer.
How to Turn “Check-the-Box” Compliance Trainings Into Real Learning
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance trainings aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, relevant, and maybe even enjoyable! Join expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training programs. You’ll discover creative strategies to turn traditionally dry topics into meaningful learning experiences that resonate and drive real change.
ConcertAI and Bayer to boost precision oncology with AI and ML insights
Pharmaceutical Technology
APRIL 23, 2025
ConcertAI has announced an agreement with Bayer that allows the latter to utilise its Translational360 and AI SaaS solutions.
Roche looks to a Flagship startup in search of new immune drugs
Bio Pharma Dive
APRIL 23, 2025
Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech division unearth T-cell targeting therapies for inflammatory diseases.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care
Bio Pharma Dive
APRIL 23, 2025
Agile biopharma firms are driving breakthroughs. Learn how they ensure clinical trial success in this podcast.
EditCo Bio secures access to Promega’s technologies in licensing deal
Pharmaceutical Technology
APRIL 23, 2025
EditCo Bio has entered a licensing agreement to secure access to Promegas protein-tagging and bioluminescent identification technologies.
Axtria unveils transformational agentic AI platform for life sciences
pharmaphorum
APRIL 23, 2025
Axtria Inc., an AI-first data analytics innovator and global provider of cloud software to the life sciences industry, today announced its next generation of Axtria InsightsMAx, powered by agentic AI.
Synthetic hormones and the future of contraception
Pharmaceutical Technology
APRIL 23, 2025
Contraception for women has seen little change over the past 50 years, with the most prevalent contraceptive pills containing synthetic hormones.
Clinical Research White Paper – Enhancing Transparency & Efficiency Throughout the Trial Lifecycle
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
Roche gets EU okay for chest pain algorithm
pharmaphorum
APRIL 23, 2025
Roche has claimed a CE Mark in the EU for an AI algorithm that can help doctors decide whether patients with chest pain are having a heart attack.
Veraxa to go public in $1.6bn SPAC deal with Voyager
Pharmaceutical Technology
APRIL 23, 2025
Veraxa Biotech will gain access to $253m in cash from Voyager to advance its cancer drug pipeline.
UCL researchers launch congenital muscular dystrophy research programme
Pharma Times
APRIL 23, 2025
The university has been awarded a 1m grant from LifeArc and Muscular Dystrophy UK
FDA layoffs and priority review voucher programme’s lapse disrupt rare disease pipeline
Pharmaceutical Technology
APRIL 23, 2025
The expiration of the FDAs paediatric priority review voucher programme is creating uncertainty for rare disease drug developers.
Can Your Organization Spot a Conflict Before It’s a Crisis?
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
Senior FDA resignations gut drug advertising function
pharmaphorum
APRIL 23, 2025
Two senior officials at the FDA's drug promotion office have resigned, leading to speculation that a clampdown on some advertising may be on the way.
LogiPharma Europe 2025: Three Ways to Turn Sustainability Pledges Into Progress
Pharmaceutical Commerce
APRIL 23, 2025
Joydeep Ganguly, SVP, corporate operations, interim CIO, Gilead Sciences, shares how stakeholders can drive meaningful, lasting impact by turning pledges into proof points, exercising patience, and embedding sustainability into core business operations.
Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal
pharmaphorum
APRIL 23, 2025
Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.
Gravity Test
Trialfacts
APRIL 23, 2025
Is This Study Not For You? Enter your details to be notified via email about new studies in your area First Name (Required) Email (Required) Country (Required) Country Australia Canada New Zealand United States Other State (Aus) (Required) State (Aus) NSW ACT NT QLD SA TAS VIC WA State (US) (Required) State (US) Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland
White Paper - A Roadmap to AI Data Readiness in R&D Labs
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
First drug for rare disease APDS cleared for NHS use
pharmaphorum
APRIL 23, 2025
Pharming's Joenja has become the first disease-modifying drug that can be used by the NHS to treat APDS, an ultra-rare immunodeficiency disorder
IATA CEIV Celebrates a Decade of Enhancing Air Cargo Efficiency
Pharmaceutical Commerce
APRIL 23, 2025
The program measures a companys air cargo supply chain efforts when it comes to quality, safety, and compliance.
Has trial result burst BMS' Cobenfy bubble?
pharmaphorum
APRIL 23, 2025
Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a failed clinical trial
Analyzing Tariffs’ Effect on the Biopharmaceutical Supply Chain
Pharmaceutical Commerce
APRIL 23, 2025
In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, outlines how US tariffs on Canadian goods have impacted the companys operations, particularly in terms of cost and supply chain management in the US market.
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bad KOL data is expensive: Harnessing high-quality data for biopharma innovation
pharmaphorum
APRIL 23, 2025
As biopharmas increasingly rely on AI and advanced data-driven technologies, evaluating the quality of data - and the costs of bad data - can help to avoid significant financial risks and missed opportunities.
April 23, 2025: In This Week’s PCT Grand Rounds, Automated Response Technology in EMR and Physician-Patient Communication
Rethinking Clinical Trials
APRIL 23, 2025
In this Friday’s PCT Grand Rounds, Ming Tai-Seale of the University of California, San Diego, will present “Automated Response Technology Integrated Into EMR and Physician-Patient Communication.” The Grand Rounds session will be held on Friday, April 25, 2025, at 1:00 pm eastern. Tai-Seale is professor and vice chair of research in the Department of Family Medicine at the University of California, San Diego, and director of the UCSD Learning Health Systems Science Center.
Shifting paradigms of clinical trial design accelerate CNS R&D
pharmaphorum
APRIL 23, 2025
Alzheimers drug developers are now at the forefront of adopting more nuanced, cost-effective, and patient-centric clinical trial designs.
Pixee’s Knee NexSight for Augmented Reality-Based Surgical Navigation Cleared by FDA
XTalks
APRIL 23, 2025
Pixee Medicals latest innovation, Knee + NexSight, has been cleared by the FDA. This is a next-gen augmented reality (AR) system designed to assist surgeons during total knee arthroplasty (TKA). Headquartered in Besanon, France, Pixee specializes in AR-based navigation systems for orthopedic surgery. Knee + NexSight aims to deliver implant positioning accuracy without the infrastructure burden of conventional robotic systems.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Changing Faces: Board appointments in March 2025
pharmaphorum
APRIL 23, 2025
Changing Faces announces new board appointments for Ascend, iOnctura, Pfizer, CAMP4 Therapeutics, and HUTCHMED in March 2025. Stay updated on the latest developments in the pharmaceutical industry.
How Is Dr. Stephen Harrison’s Legacy Continuing to Accelerate MASH Clinical Research?
XTalks
APRIL 23, 2025
Dr. Stephen Harrisons pioneering work in liver research has left an indelible mark on the medical community. Over a 30-year career, he not only advanced the understanding of metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) but also played a critical role in the development of the first FDA-approved drug for these conditions.
Smaller Pharmacies, Bigger Impact: Inside Manufacturers’ Specialty Networks in 2025
Drug Channels
APRIL 23, 2025
Last week, we examined the growing concentration of specialty drug dispensing revenues among the largest pharmacies. See The Top 15 Specialty Pharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market. Today, we dive deeper. Drawing from DCIs new 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers , we explore how pharmaceutical manufacturers structure their specialty pharmacy networksand how smaller, independent pharmacies have emerged as dominant pl
The Impact of Drug Patent Expiration: Financial Implications, Lifecycle Strategies, and Market Transformations
Drug Patent Watch
APRIL 23, 2025
"Patent Expiration: The $1.4 Trillion Wake-Up Call for the Pharmaceutical Industry As the pharmaceutical landscape continues to shift, one thing is clear: the expiration of drug patents is no longer a footnote in the industry's financials. According to a recent analysis, the loss of exclusivity for top-selling medications will result in a staggering $1.4 trillion in lost revenue by 2025.
Let's personalize your content